JP2021517119A - 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 - Google Patents
腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 Download PDFInfo
- Publication number
- JP2021517119A JP2021517119A JP2020546331A JP2020546331A JP2021517119A JP 2021517119 A JP2021517119 A JP 2021517119A JP 2020546331 A JP2020546331 A JP 2020546331A JP 2020546331 A JP2020546331 A JP 2020546331A JP 2021517119 A JP2021517119 A JP 2021517119A
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- inhibitor
- cdk4
- combination
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(N(c([s]c(C)c1C)c1C(c(cc1)ccc1Cl)=N[C@]1CC(Nc(cc2)ccc2O)=*)C1=[N+])=N Chemical compound CC(N(c([s]c(C)c1C)c1C(c(cc1)ccc1Cl)=N[C@]1CC(Nc(cc2)ccc2O)=*)C1=[N+])=N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024186627A JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000210 | 2018-03-05 | ||
| EP18000210.7 | 2018-03-05 | ||
| PCT/EP2019/000067 WO2019170283A1 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024186627A Division JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517119A true JP2021517119A (ja) | 2021-07-15 |
| JP2021517119A5 JP2021517119A5 (cg-RX-API-DMAC7.html) | 2022-03-14 |
Family
ID=61569019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546331A Pending JP2021517119A (ja) | 2018-03-05 | 2019-03-05 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
| JP2024186627A Pending JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024186627A Pending JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210038661A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3762004B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021517119A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210031852A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112533620B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019232768B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092907A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3762004T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965632T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3762004T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE064471T2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007873VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019170283A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022547885A (ja) * | 2019-09-05 | 2022-11-16 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 |
| WO2024043322A1 (ja) * | 2022-08-25 | 2024-02-29 | 富士フイルム株式会社 | 目的ウイルスの製造方法、および培養組成物 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102341347B1 (ko) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006512284A (ja) * | 2002-05-27 | 2006-04-13 | ホルム,ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2006518589A (ja) * | 2002-10-15 | 2006-08-17 | ホルム,ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
| JP2007511212A (ja) * | 2003-11-14 | 2007-05-10 | ホルム,ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
| JP2016516407A (ja) * | 2013-03-14 | 2016-06-09 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| WO2016178167A1 (en) * | 2015-05-04 | 2016-11-10 | Vcn Biosciences Sl | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
| JP2017501187A (ja) * | 2013-12-31 | 2017-01-12 | シュエンジュウ・ファーマ・カンパニー・リミテッド | キナーゼ阻害剤及びその使用 |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| US9271988B2 (en) * | 2011-07-01 | 2016-03-01 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer |
| AU2014272695B2 (en) * | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
-
2019
- 2019-03-05 SG SG11202007873VA patent/SG11202007873VA/en unknown
- 2019-03-05 DK DK19710999.4T patent/DK3762004T3/da active
- 2019-03-05 US US16/978,048 patent/US20210038661A1/en active Pending
- 2019-03-05 KR KR1020207025771A patent/KR20210031852A/ko not_active Ceased
- 2019-03-05 JP JP2020546331A patent/JP2021517119A/ja active Pending
- 2019-03-05 CN CN201980016785.2A patent/CN112533620B/zh active Active
- 2019-03-05 EP EP19710999.4A patent/EP3762004B1/en active Active
- 2019-03-05 KR KR1020267017074A patent/KR20260089640A/ko active Pending
- 2019-03-05 WO PCT/EP2019/000067 patent/WO2019170283A1/en not_active Ceased
- 2019-03-05 HU HUE19710999A patent/HUE064471T2/hu unknown
- 2019-03-05 CA CA3092907A patent/CA3092907A1/en active Pending
- 2019-03-05 ES ES19710999T patent/ES2965632T3/es active Active
- 2019-03-05 AU AU2019232768A patent/AU2019232768B2/en active Active
- 2019-03-05 FI FIEP19710999.4T patent/FI3762004T3/fi active
-
2024
- 2024-10-23 JP JP2024186627A patent/JP2025013934A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006512284A (ja) * | 2002-05-27 | 2006-04-13 | ホルム,ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2006518589A (ja) * | 2002-10-15 | 2006-08-17 | ホルム,ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
| JP2007511212A (ja) * | 2003-11-14 | 2007-05-10 | ホルム,ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
| JP2016516407A (ja) * | 2013-03-14 | 2016-06-09 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| JP2017501187A (ja) * | 2013-12-31 | 2017-01-12 | シュエンジュウ・ファーマ・カンパニー・リミテッド | キナーゼ阻害剤及びその使用 |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| WO2016178167A1 (en) * | 2015-05-04 | 2016-11-10 | Vcn Biosciences Sl | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
Non-Patent Citations (7)
| Title |
|---|
| ANAL. BIOCHEM., vol. 421, JPN6024024291, 2012, pages 368 - 377, ISSN: 0005354480 * |
| CANCER TREAT. REV., vol. 45, JPN6024024290, 2016, pages 129 - 138, ISSN: 0005354481 * |
| DIGESTIVE DISEASES AND SCIENCES,2008年,VOL. 54,NO. 7,P.1425-1431, JPN6022054131, ISSN: 0005144309 * |
| EUROPEAN UROLOGY SUPPLEMENTS, vol. 14, no. 2, JPN6022054129, 2015, pages 32, ISSN: 0005144308 * |
| MOLECULAR ONCOLOGY, vol. 9, no. 4, JPN6022054132, 2014, pages 791 - 805, ISSN: 0005144310 * |
| NATURE COMMUNICATIONS,2022年8月10日,VOL. 13,NO. 1, #4689, JPN6022054134, ISSN: 0005144307 * |
| VIRUSES,2010年,VOL. 2,NO. 1,P.78-106, JPN6022054133, ISSN: 0005144306 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022547885A (ja) * | 2019-09-05 | 2022-11-16 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 |
| JP7834342B2 (ja) | 2019-09-05 | 2026-03-24 | クリニクム デア テクニシェン ウニフェルジテート ミュンヘン(ティーユーエム クリニクム) | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 |
| WO2024043322A1 (ja) * | 2022-08-25 | 2024-02-29 | 富士フイルム株式会社 | 目的ウイルスの製造方法、および培養組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019170283A8 (en) | 2019-11-07 |
| CA3092907A1 (en) | 2019-09-12 |
| CN112533620A (zh) | 2021-03-19 |
| AU2019232768B2 (en) | 2025-12-18 |
| HUE064471T2 (hu) | 2024-03-28 |
| EP3762004B1 (en) | 2023-09-13 |
| EP3762004A1 (en) | 2021-01-13 |
| DK3762004T3 (da) | 2023-11-27 |
| AU2019232768A1 (en) | 2020-09-03 |
| CN112533620B (zh) | 2025-03-28 |
| US20210038661A1 (en) | 2021-02-11 |
| SG11202007873VA (en) | 2020-09-29 |
| ES2965632T3 (es) | 2024-04-16 |
| KR20260089640A (ko) | 2026-06-15 |
| RU2020132466A (ru) | 2022-04-05 |
| JP2025013934A (ja) | 2025-01-28 |
| KR20210031852A (ko) | 2021-03-23 |
| RU2020132466A3 (cg-RX-API-DMAC7.html) | 2022-04-05 |
| WO2019170283A1 (en) | 2019-09-12 |
| FI3762004T3 (fi) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5618896B2 (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| JP6375273B2 (ja) | 腫瘍選択的e1aおよびe1b変異体 | |
| JP5873893B2 (ja) | アデノウイルスおよびそれをコードしている核酸の新たな使用 | |
| JP2025013934A (ja) | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 | |
| JP6388593B2 (ja) | E1bタンパク質の156rスプライシングアイソフォームの割合を増加させた腫瘍溶解性アデノウイルス | |
| US20090270484A1 (en) | WWOX Vectors and Uses in Treatment of Cancer | |
| KR101527213B1 (ko) | 동물 세포에서 다중 내성을 역전시키기 위한 방법 | |
| Holzmüller et al. | YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma | |
| JP7834342B2 (ja) | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 | |
| KR20050061530A (ko) | 신규한 아데노바이러스, 이를 암호화하는 핵산 및 이들의용도 | |
| KR20040077002A (ko) | 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터 | |
| RU2835886C1 (ru) | Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента | |
| RU2811278C2 (ru) | Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6 | |
| Wang et al. | HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| WO2018067165A1 (en) | Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer | |
| Kühnel et al. | Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues | |
| Li et al. | microRNA response element‑regulated TIKI2 expression suppresses the tumorigencity of malignant gliomas | |
| Klein | Investigation of replication kinetics and cell killing capacity of the oncolytic adenovirus XVir-N-31 in conjunction with targeted therapy | |
| Majhen et al. | Vincristine-resistant human laryngeal carcinoma cells demonstrate increased Rous sarcoma virus promoter activity | |
| Aguirre | The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy | |
| Wang et al. | Research HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| Abbas | UNDERSTANDING THE RELATIONSHIP BETWEEN ONCOLYTIC AD5 DELETED E1b55KDA LYTIC INFECTION AND P53 IN MAMMALIAN CELLS | |
| Strauss | ANALYSIS OF RESISTANCE OF PRIMARY OVARIAN CANCER CELLS TO VIRAL ONCOLYSIS DISSER TAT ION zur Erlangung des akademischen Grades doctor rerum naturalium | |
| Rivera Gonzalez | Regulation of the prostate-specific hTGP (TGM4) gene and its potential use for prostate cancer gene therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220302 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220302 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230626 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240304 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240625 |